Lillquist J S, Simon P L, Summers M, Jonak Z, Young P R
Department of Molecular Genetics, Smith Kline and French Laboratories, King of Prussia, PA 19406-0939.
J Immunol. 1988 Sep 15;141(6):1975-81.
IL-1 beta is synthesized as an inactive 31-kDa intracellular protein, which is then processed upon secretion to an active 17-kDa carboxyl-terminal fragment. To identify the minimal portion of IL-1 beta required for activity, we constructed several deletion mutants of mature IL-1 beta. These included three amino-terminal deletions of 10, 16, and 81 amino acids, two carboxyl-terminal deletions of 17 and 72 amino acids, and one internal fragment between amino acids 17 and 81. Expression of the mutants was monitored by Western blots and immunoprecipitation. With one exception, all of these mutants and the full length 17-kDa IL-1 beta were expressed as soluble protein in Escherichia coli and could be assayed for activity and receptor binding in lysates without further purification. Whereas the intact 17-kDa IL-1 beta retained full biologic activity (greater than 10(7) U/ml of lysate) and competed for binding with 125I-labeled IL-1 beta, none of the lysates containing IL-1 beta deletion mutant proteins had activity or competed for binding to receptor at significantly higher concentrations. The loss of function in the smallest C-terminal deletion mutant does not appear to be due to the direct involvement of these C-terminal residues in receptor binding because both monoclonal and polyclonal antisera directed to this region bind to IL-1 beta but do not neutralize its activity. Therefore, this region is probably indirectly involved in sustaining the structure of the receptor-binding site.
白细胞介素-1β(IL-1β)最初作为一种无活性的31 kDa细胞内蛋白被合成,随后在分泌时被加工成有活性的17 kDa羧基末端片段。为了确定IL-1β发挥活性所需的最小部分,我们构建了几个成熟IL-1β的缺失突变体。这些突变体包括三个分别缺失10、16和81个氨基酸的氨基末端缺失突变体,两个分别缺失17和72个氨基酸的羧基末端缺失突变体,以及一个位于第17至81个氨基酸之间的内部片段。通过蛋白质免疫印迹法和免疫沉淀法监测突变体的表达。除了一个例外,所有这些突变体以及全长17 kDa的IL-1β在大肠杆菌中均以可溶性蛋白形式表达,无需进一步纯化即可在裂解物中检测其活性和受体结合情况。完整的17 kDa IL-1β保留了全部生物学活性(裂解物活性大于10⁷ U/ml),并能与¹²⁵I标记的IL-1β竞争结合,但含有IL-1β缺失突变体蛋白的裂解物均无活性,且在显著更高浓度下也不能竞争结合受体。最小的羧基末端缺失突变体功能丧失似乎并非由于这些羧基末端残基直接参与受体结合,因为针对该区域的单克隆和多克隆抗血清均能与IL-1β结合,但不能中和其活性。因此,该区域可能间接参与维持受体结合位点的结构。